Pierre Fabre Advances Two Phase II Trials of Encorafenib in Chinese Patients with BRAF V600E Mutations
核心洞察
Pierre Fabre (搜索) is conducting two Phase II clinical trials evaluating encorafenib (Braftovi®) in Chinese patients with BRAF V600E (搜索) mutant solid tumors (搜索) and metastatic colorectal cancer (搜索).
The NAUTICAL trial compares encorafenib plus cetuximab combination therapy against standard FOLFIRI (搜索)/cetuximab treatment in Chinese patients with BRAF V600E (搜索) mutant metastatic colorectal cancer (搜索).
The OCEAN-I trial focuses on investigating the safety profile of encorafenib as monotherapy or combination therapy specifically in Chinese patients with BRAF V600E (搜索) solid tumors (搜索).
Pierre Fabre (搜索) is conducting two pivotal Phase II clinical trials to evaluate the safety and efficacy of encorafenib (Braftovi®) in Chinese patients with BRAF V600E (搜索) mutations, addressing a significant gap in clinical data for this patient population despite the drug's established international approval.
NAUTICAL Trial Targets Metastatic Colorectal Cancer
The NAUTICAL trial (NCT05004350) represents a multicenter, randomized, open-label, 2-arm Phase II study with a safety lead-in phase evaluating encorafenib in combination with cetuximab versus standard care in Chinese patients with BRAF V600E (搜索) mutant metastatic colorectal cancer (搜索). The study compares the encorafenib/cetuximab combination against irinotecan/cetuximab or FOLFIRI (搜索)/cetuximab regimens.
Previous clinical trials have demonstrated that encorafenib in combination with cetuximab is effective for treating patients with metastatic colorectal cancer (搜索) carrying the BRAF V600E (搜索) mutation. The combination is currently approved and marketed in several countries including the European Union, USA, Australia, Japan, and Switzerland for patients whose disease had worsened following prior systemic therapies.
The trial aims to prove that this combination would present the same benefits for Chinese patients, addressing the therapeutic area of oncology specifically for BRAF V600E (搜索) metastatic colorectal cancer (搜索). The study is currently active and enrolls patients aged 18 years and older of all genders.
OCEAN-I Study Evaluates Broader Solid Tumor Applications
The OCEAN-I trial focuses on investigating the safety of encorafenib in Chinese participants with BRAF V600E (搜索) solid tumors (搜索). This study addresses the limited clinical information available for encorafenib used as monotherapy or in combination with other drugs specifically in Chinese patients whose tumors harbor the BRAF V600E mutation.
Encorafenib is already a marketed drug approved to treat patients with certain skin cancer (melanoma (搜索)) and certain colorectal cancer in multiple international markets. However, the specific safety and efficacy profile in Chinese patients remains understudied, creating the rationale for this dedicated investigation.
Addressing Clinical Data Gaps in Chinese Populations
Both trials represent Pierre Fabre (搜索)'s strategic approach to generating region-specific clinical evidence for encorafenib in Chinese patients. The studies acknowledge that while encorafenib has demonstrated efficacy in international populations, limited clinical information exists specifically for Chinese patients with BRAF V600E (搜索) mutations.
The BRAF V600E (搜索) mutation represents a critical therapeutic target in oncology, and these trials will provide essential data to support potential regulatory submissions and clinical decision-making in the Chinese healthcare system. The studies utilize established combination partners, with cetuximab (Erbitux®) serving as the key combination agent in the NAUTICAL trial.
These Phase II trials follow standard oncology development pathways, incorporating safety lead-in phases and randomized controlled designs to generate robust clinical evidence for this patient population.